


Stabilis



Aciclovir sodium



Noms commerciaux

Abaciclovir	Brésil
Abbovir	Pologne
Acevir	Pérou
Acic	Allemagne
Aciclobene	Autriche
Acicloget	Pérou
Aciclovax	Portugal
Aciclovir	Allemagne, Argentine, Australie, Belgique, Chili, Colombie, Egypte, Equateur, Espagne, Finlande, France, Grande Bretagne, Iran, Irlande, Italie, Luxembourg, Malaisie, Norvège, Nouvelle Zélande, Pérou, Pologne, Suède, Tunisie
Acivir	Inde
Acix	Pologne
Acyclovir	Canada, Danemark, Emirats Arabes Unis, Etats Unis d'Amérique, Finlande, Malaisie, Suède, Suisse
Acyrax	Finlande
Antivirax	Brésil
Axovir	Inde
Cevirin	Inde
Cicloferon	Mexique
Cicloviral	Maroc, Portugal
Cusiviral	Espagne
Cycloviran	Italie
Eurovir	Chili
Geavir	Danemark, Finlande, Suède
Herpesin	Hongrie, Pologne
Herzovir	Inde, Malaisie
Isavir	Colombie, Mexique
Klorvireks	Malaisie, Turquie
Lafevir	Argentine
Lovir	Inde
Lovrak	Arabie Saoudite, Emirats Arabes Unis
Maynar	Espagne
Medovir	Malaisie
Mevirox	Tunisie
Nisivir	Inde
Nycovir	Autriche
Olcicavar	Mexique

Ovir	Inde
Sanavir	Italie
Supraviran	Allemagne, Egypte, Emirats Arabes Unis
Trixviral	Argentine
Vacrax	Inde, Malaisie
Vircidal	Colombie
Virex	Colombie
Virherpes	Espagne
Virmen	Espagne
Virolex	Hongrie, Pologne, Roumanie
Virulax	Vénézuela
Xiclovir	Argentine
Xorox	Autriche
Zovir	Islande
Zovirax	Allemagne, Arabie Saoudite, Australie, Autriche, Belgique, Brésil, Chili, Colombie, Egypte, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Grèce, Inde, Iran, Irlande, Italie, Luxembourg, Malaisie, Maroc, Mexique, Pays bas, Pologne, Suède, Suisse, Tunisie, Turquie
Zoylex	Inde, Pérou



Stabilité des solutions

PVC	▲▲	1 & 7 & 10 mg/ml	4°C		35	◐		822
PVC	▲▲	5 mg/ml	25°C	?	37	◐		68
PVC	▲▲	5 mg/ml	5°C		37	◐		68
PVC	▲	1 & 7 & 10 mg/ml	23°C		7	◐		822
PVC	◆	1 & 7 & 10 mg/ml	23°C		21	◐		822
PE	▲▲	5 mg/ml	22°C		24	☑		1067
PE	▲▲	5 mg/ml	4°C		24	☑		1067
PP	▲	5 mg/ml	2-8°C	?	63	◐		4573
POF	▲	5 mg/ml	-20°C		90	◐		3001
POF	▲	5 mg/ml	2-8°C	?	21	◐		3001
	▲	10 mg/ml	25°C	?	30	◐		1717
PI	▲	1 & 10 mg/ml	25°C	?	4	◐		604
SI	▲	0,83 mg/ml	19°C		14	◐		4792
SI	▲	10 mg/ml	19°C		14	◐		4792



Facteur influençant la stabilité

				1415 3595
				301 1868 3595
				3595



Compatibilités

		Aciclovir sodium		3595
		Aciclovir sodium		3595
		Aciclovir sodium : 7 mg/ml Amifostine : 10 mg/ml		3
		Aciclovir sodium : 5 mg/ml Amikacin sulfate : 5 mg/ml		336
		Aciclovir sodium : 7 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Aciclovir sodium : 5 mg/ml Ampicillin sodium : 20 mg/ml		336
		Aciclovir sodium : 7 mg/ml Amsacrine : 1 mg/ml		253
		Aciclovir sodium : 7 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Aciclovir sodium : 50 mg/ml	RL	4603
		Aciclovir sodium : 1.096 >> 1.5 mg/ml		1868
		Aciclovir sodium : 50 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Aciclovir sodium : 7 mg/ml		1415
		Aciclovir sodium : 7 mg/ml		301
		Aciclovir sodium Amifostine		3595
		Aciclovir sodium Amsacrine		3595
		Aciclovir sodium		3595
		Aciclovir sodium		3985
		Aciclovir sodium : 7 mg/ml		316

		Aciclovir sodium : 7 mg/ml Allopurinol sodium : 3 mg/ml		307
		Aciclovir sodium : 7 mg/ml Aztreonam : 40 mg/ml		99
		Aciclovir sodium Aztreonam		3595
		Aciclovir sodium : 50 mg/ml Caffeine : 10 mg/ml		3964
		Aciclovir sodium : 7 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Aciclovir sodium : 5 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Aciclovir sodium : 5 mg/ml Cefamandole nafate : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Cefazolin sodium : 20 mg/ml		336
		Aciclovir sodium : 7 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Aciclovir sodium : 5 mg/ml Cefonicid sodium : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Cefoperazone sodium : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Ceforanide : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Cefotaxime sodium : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Cefoxitin sodium : 20 mg/ml		336
		Aciclovir sodium : 7 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Aciclovir sodium : 7 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Aciclovir sodium : 5 mg/ml Ceftazidime : 20 mg/ml		336
		Aciclovir sodium Ceftazidime		3883
		Aciclovir sodium : 5 mg/ml Ceftizoxime sodium : 20 mg/ml		336
		Aciclovir sodium Ceftobiprole medocaril sodium		4650
		Aciclovir sodium : 7 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Aciclovir sodium : 7 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Aciclovir sodium : 5 mg/ml Ceftriaxone disodium : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Cefuroxime sodium : 15 mg/ml		336
		Aciclovir sodium : 5 mg/ml Chloramphenicol sodium succinate : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Ciclosporin : 1 mg/ml		2335

		Aciclovir sodium : 5 mg/ml Cimetidine hydrochloride : 6 mg/ml		336
		Aciclovir sodium : 7 mg/ml Cisatracurium besylate : 0.1 & 2 mg/ml		299
		Aciclovir sodium : 7 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Aciclovir sodium : 5 mg/ml Clindamycin phosphate : 12 mg/ml		336
		Aciclovir sodium : 50 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Aciclovir sodium : 5 mg/ml Co-trimoxazole : 4/0.8 mg/ml		336
		Aciclovir sodium Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Aciclovir sodium : 10 mg/ml Defibrotide : 8 mg/ml		3728
		Aciclovir sodium : 5 mg/ml Dexamethasone sodium phosphate : 0.2 mg/ml		336
		Aciclovir sodium : 5 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		2335
		Aciclovir sodium Diltiazem hydrochloride		3595
		Aciclovir sodium : 7 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Aciclovir sodium : 5 & 7 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Aciclovir sodium : 5 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Aciclovir sodium : 5 mg/ml Dimenhydrinate : 1 mg/ml		336
		Aciclovir sodium : 5 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		2335
		Aciclovir sodium : 5 mg/ml Diphenhydramine hydrochloride : 1 mg/ml		336
		Aciclovir sodium : 5 mg/ml Dobutamine hydrochloride : 1 mg/ml		336
		Aciclovir sodium Dobutamine hydrochloride		3595
		Aciclovir sodium : 7 mg/ml Docetaxel : 0.9 mg/ml		1754
		Aciclovir sodium : 5 mg/ml Dopamine hydrochloride : 1.6 mg/ml		336
		Aciclovir sodium Dopamine hydrochloride		3595
		Aciclovir sodium : 7 mg/ml Doripenem : 5 mg/ml		2262
		Aciclovir sodium : 7 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Aciclovir sodium : 5 mg/ml Doxycycline hyclate : 1 mg/ml		336
		Aciclovir sodium : 5 mg/ml Droperidol : 2,5 mg/ml		2335

		Aciclovir sodium : 5 mg/ml Erythromycin lactobionate : 4 mg/ml		336
		Aciclovir sodium : 7 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Aciclovir sodium : 7 mg/ml Famotidine : 2 mg/ml		215
		Aciclovir sodium : 5 mg/ml Fentanyl citrate : 50 µg/ml		2335
		Aciclovir sodium : 7 mg/ml Filgrastim : 30 µg/ml		244
		Aciclovir sodium : 10 mg/ml Fluconazole : 2 mg/ml		496
		Aciclovir sodium : 10 mg/ml Fluconazole : 2 mg/ml		256
		Aciclovir sodium : 7 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Aciclovir sodium Fludarabine phosphate		3595
		Aciclovir sodium Foscarnet sodium		3595
		Aciclovir sodium Foscarnet sodium		3662
		Aciclovir sodium : 10 mg/ml Foscarnet sodium : 24 mg/ml		73
		Aciclovir sodium : 7 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Aciclovir sodium : 7 mg/ml Gallium nitrate : 1 mg/ml		91
		Aciclovir sodium : 7 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Aciclovir sodium : 5 mg/ml Gentamicin sulfate : 1.6 mg/ml		336
		Aciclovir sodium : 5 mg/ml Gentamicin sulfate : 30 mg/ml		2335
		Aciclovir sodium : 7 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Aciclovir sodium : 5 mg/ml Granisetron hydrochloride : 1 mg/ml		2335
		Aciclovir sodium : 5 mg/ml Heparin sodium : 50 UI/ml		336
		Aciclovir sodium : 5 mg/ml Heparin sodium : 100 UI/ml		2335
		Aciclovir sodium : 5 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		336
		Aciclovir sodium : 5 mg/ml Hydromorphone hydrochloride : 0.04 mg/ml		336
		Aciclovir sodium : 5 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Aciclovir sodium Idarubicin hydrochloride		3595
		Aciclovir sodium : 5 mg/ml Imipenem - cilastatin sodium : 5/5 mg/ml		336

		Aciclovir sodium : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Aciclovir sodium : 7 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Aciclovir sodium : 50 mg/ml Levofloxacin : 5 mg/ml		1072
		Aciclovir sodium : 7 mg/ml Linezolid : 2 mg/ml		1925
		Aciclovir sodium : 5 mg/ml Lorazepam : 0.04 mg/ml		336
		Aciclovir sodium : 5 mg/ml Magnesium sulfate : 20 mg/ml		336
		Aciclovir sodium : 7 mg/ml Melphalan : 0.1 mg/ml		169
		Aciclovir sodium Meropenem		3595
		Aciclovir sodium : 5 mg/ml Meropenem : 20 mg/ml		266
		Aciclovir sodium : 5 mg/ml Meropenem : 1 & 50 mg/ml		266
		Aciclovir sodium : 5 mg/ml Methylprednisolone sodium succinate : 0.8 mg/ml		336
		Aciclovir sodium : 5 mg/ml Metoclopramide hydrochloride : 0.2 mg/ml		336
		Aciclovir sodium : 5 mg/ml Metoclopramide hydrochloride : 5 mg/ml		2335
		Aciclovir sodium : 5 mg/ml Metronidazole : 5 mg/ml		336
		Aciclovir sodium Morphine sulfate		3531
		Aciclovir sodium : 5 mg/ml Morphine sulfate : 0.08 mg/ml		336
		Aciclovir sodium : 5 mg/ml Morphine sulfate : 1 mg/ml		62
		Aciclovir sodium Morphine sulfate		3595
		Aciclovir sodium : 50 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Aciclovir sodium : 5 mg/ml Nafcillin sodium : 20 mg/ml		336
		Aciclovir sodium : 5 mg/ml Nalbuphine hydrochloride : 10 mg/ml		2335
		Aciclovir sodium : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Aciclovir sodium Ondansetron hydrochloride		3595
		Aciclovir sodium : 7 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Aciclovir sodium : 5 mg/ml Oxacillin sodium : 20 mg/ml		336
		Aciclovir sodium : 7 mg/ml Paclitaxel : 1.2 mg/ml		248

		Aciclovir sodium Pantoprazole sodium		2090
		Aciclovir sodium : 5 mg/ml Paracetamol : 10 mg/ml	∅	3571
		Aciclovir sodium : 50 mg/ml Paracetamol : 10 mg/ml		4742
		Aciclovir sodium : 7 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Aciclovir sodium : 5 mg/ml Penicillin G potassium : 0.04 MUI/ml		336
		Aciclovir sodium : 5 mg/ml Pentobarbital sodium : 2 mg/ml		336
		Aciclovir sodium : 5 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Aciclovir sodium Pethidine hydrochloride		3595
		Aciclovir sodium : 5 mg/ml Pethidine hydrochloride : 100 mg/ml		132
		Aciclovir sodium : 5 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Aciclovir sodium : 5 mg/ml Pethidine hydrochloride : 1 mg/ml		336
		Aciclovir sodium : 5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Aciclovir sodium : 5 mg/ml Piperacillin sodium : 60 mg/ml		336
		Aciclovir sodium : 7 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Aciclovir sodium Piperacillin sodium / tazobactam		3595
		Aciclovir sodium : 3,5 mg/ml Posaconazole : 1,2 mg/ml		4521
		Aciclovir sodium : 5 mg/ml Potassium chloride : 40 mEq/l		336
		Aciclovir sodium : 7 mg/ml Propofol : 10 mg/ml	∅	300
		Aciclovir sodium : 5 mg/ml Ranitidine hydrochloride : 1 mg/ml		336
		Aciclovir sodium : 7 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Aciclovir sodium : 50 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Aciclovir sodium : 7 mg/ml Sargramostim : 10 µg/ml		335
		Aciclovir sodium Sargramostim		3595
		Aciclovir sodium : 5 mg/ml Sodium bicarbonate : 42 mg/ml		336
		Aciclovir sodium Tacrolimus		3626
		Aciclovir sodium : 10 mg/ml Tacrolimus : 1000 µg/ml		479

	Aciclovir sodium : 7 mg/ml Teniposide : 0.1 mg/ml		905	
	Aciclovir sodium : 5 mg/ml Theophylline : 1.6 mg/ml		336	
		Aciclovir sodium : 50 mg/ml Thiopental sodium : 25 mg/ml		3767
	Aciclovir sodium : 7 mg/ml Thiotepa : 1 mg/ml		249	
	Aciclovir sodium : 5 mg/ml Tobramycin sulfate : 1.6 mg/ml		336	
		Aciclovir sodium : 5 mg/ml Tramadol hydrochloride : 0,4 mg/ml		2002
	Aciclovir sodium : 5 mg/ml Vancomycin hydrochloride : 5 mg/ml		336	
		Aciclovir sodium : 7 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Aciclovir sodium Vinorelbine tartrate		3595
	Aciclovir sodium : 7 mg/ml Zidovudine : 4 mg/ml		337	



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
68	Revue	Das Gupta V, Pramar Y, Bethea C. Stability of acyclovir sodium in dextrose and sodium chloride injections. J Clin Pharm Ther 1989 ; 14: 451-456.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.

84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
132	Revue	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
256	Revue	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
822	Revue	Zhang Y, Trissel LA, Martinez JF, Gilbert DL. Stability of acyclovir sodium 1, 7, and 10 mg/ml in 5% dextrose injection and in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1998 ; 55: 574-577.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.

























































1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1717	Revue	Ling J, Das Gupta V. Stability of acyclovir sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2001 ; 5: 75-77.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1868	Revue	Husson E, Crauste-Manciet S, Hadj-Salah E, Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2002	Revue	Abanmy NO, Zaghoul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.

2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3001	Revue	Dewulf J, Galanti L, Godet M, Gillet P, Jamart J, Hecq JD. Long-term stability of aciclovir in 0.9% NaCl infusion polyolefin bags at 2-8°C after freeze-thaw treatment: A generic product versus the brand name. Ann Pharm Fr 2015 ; 73: 108-113.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Évaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3626	Laboratoire	Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit Astellas Pharma 2014
3662	Laboratoire	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apiph Congress, Paris November 2014 2014

3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3985	Poster	Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M. Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro. Hopipharm Congress 2017 - Nancy 2017
4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4573	Revue	Legeron R, Bougueon G, Berroneau A, De-Germay S, Bernadou JM, Djabarouti S, Crauste-Manciet S, Xuereb F. Long-term physicochemical stability of acyclovir 5 mg/mL solution stored in polypropylene bags as a simulated hospital stock preparation. Am J Health-Syst Pharm 2021 ;78, 9:806–812,
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftibiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4792	Revue	Sime F.B, Wallis S, Jamieson C, Hills T, Gilchrist M, Santillo M, Seaton R.A, Drummond F, Roberts J. Evaluation of the stability of aciclovir in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. EJHP 2023



Dictionnaire

 Antiviral	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Jour	 Non précisée
 Chlorure de sodium 0,9%	 Glucose 5%
 Polyéthylène	 Heure
 Polypropylène	 Polyoléfine
 Seringue polypropylène	 Elastomère en polyisoprène
 Elastomère en silicone	 Facteur influençant la stabilité
 Solvant	 Nutrition parentérale (mélange ternaire)
 Provoque	 Dégradation
 Nutrition parentérale (mélange binaire)	 Eau ppi + bactériostatique
 Compatibilités	 Molécule
 Incompatibilité non précisée	 Incompatible
 Précipitation en 1 heure	 Compatible
 Précipitation immédiate	 RL Ringer lactate
 Aucun	 Eau pour préparation injectable
 Turbidité immédiate	 Changement de couleur après 1 heure
 Changement de couleur après 2 heures	 Changement de couleur à 4 heures
 Précipitation en 2 heures	 Précipitation en 4 heures
 Incompatibilité subvisuelle	 Voie d'administration
 Perfusion intraveineuse	 Intrapéritonéale
 Bibliographie	 Dictionnaire